Bayer AG Price & Performance (BAYRY)

Bayer reported stable first-quarter sales at €13.7 billion, with strong growth in its pharmaceuticals division offsetting crop science weakness. The company confirmed its 2025 guidance, but legal risks from ongoing glyphosate litigation and currency headwinds remain significant challenges. Bayer continues cost-cutting, including 2,000 job reductions in Q1.123

After a sharp rise following better-than-expected Q1 results, Bayer shares quickly lost momentum, reflecting persistent concerns over litigation and declining earnings. Analysts note that while pharmaceutical growth is encouraging, unresolved legal liabilities and regulatory uncertainty continue to weigh on the stock’s outlook and limit upside potential.456

Bayer’s leadership highlights rapid progress in its pharmaceuticals pipeline, with nine positive Phase III results since late 2023. The company is launching new drugs to offset patent expirations and aims to contain litigation by 2026. However, 2025 is expected to be the toughest year of its turnaround.789